The latest news for pharma industry insiders.
The Impact of Alzheimer’s Disease Treatments on Health Equity
Could health system changes that improve patient access to medication have a positive effect on societal welfare?
Spread of Seasonal Flu Returns to Pre-Pandemic Levels After End of COVID-19 Global Emergency
Increased global capacity for surveillance could help monitor seasonal influenza to reduce the risk of vaccine mismatch and inform effective interventions.
Trump Wants RFK Jr. to ‘Go Wild’ on Healthcare. Investors Need Not Panic
The vaccine skeptic may find it hard to enact sweeping changes to American healthcare.
National Ataxia Foundation Hosts Congressional Briefing with Bill Nye, The Science Guy
The National Ataxia Foundation (NAF) partnered with members of Congress to host an informational meeting for legislators, their staff and other interested parties to provide education regarding Spinocerebellar Ataxia (SCA), a group of rare and debilitating hereditary neurodegenerative diseases that frequently impact multiple family members at the same time, with no cure or FDA-approved treatment.
EVERSANA on LinkedIn
Expanding Horizons! Last month, we announced the opening of our new office in Berlin, marking a significant step in our European expansion. As Mike Ryan explains in this interview with Pharmaceutical Executive, this move strengthens our ability to navigate diverse regulatory landscapes and deliver tailored solutions to meet local healthcare needs.
#GlobalExpansion #Pharmaceuticals #Berlin
Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs
Yescarta Demonstrates Promise in Treating Relapsed/Refractory Large B-Cell Lymphoma
December 9th 2024Real-world evidence from the largest analysis of second-line treatment with Yescarta in 2022-2023 demonstrated a high overall survival rate in patients with relapsed/refractory large b-cell lymphoma.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.